stella
beta
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma — Stella
Recruiting
Back to Recurrent Plasma Cell Myeloma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
City of Hope Medical Center, Duarte, California
View full record on ClinicalTrials.gov